A revolutionary advancement in ophthalmology, spearheaded by Stanford Medicine and an international consortium of researchers, has demonstrated the remarkable ability to partially restore vision in individuals suffering from advanced age-related macular degeneration (AMD). The groundbreaking technology involves a minuscule, wireless chip implanted at the back of the eye, working in tandem with a sophisticated pair of smart glasses. In a pivotal clinical study, a significant majority of participants—27 out of 32—experienced a restoration of their ability to read within a year of receiving the implant, marking a monumental leap forward in the quest to combat irreversible blindness.

This cutting-edge system, christened PRIMA, has emerged as the first prosthetic eye device capable of restoring functional vision to individuals whose sight loss was previously considered untreatable. The PRIMA implant, a testament to decades of relentless scientific pursuit, empowers patients to discern shapes and patterns, a critical level of visual perception known as form vision. Dr. Daniel Palanker, a professor of ophthalmology at Stanford Medicine and a co-senior author of the study, emphasized the profound significance of this achievement. "All previous attempts to provide vision with prosthetic devices resulted in basically light sensitivity, not really form vision," he stated. "We are the first to provide form vision." The collaborative research effort was co-led by Dr. José-Alain Sahel, professor of ophthalmology at the University of Pittsburgh School of Medicine, with Dr. Frank Holz of the University of Bonn in Germany serving as the lead author. The study’s groundbreaking findings were formally published on October 20th in the prestigious New England Journal of Medicine, solidifying its impact on the medical community.

The PRIMA system is ingeniously designed with two integral components: a compact camera integrated into a pair of specialized glasses and a wireless chip surgically implanted within the retina. The camera functions by capturing visual information from the external environment. This captured data is then transmitted via infrared light to the retinal implant. Upon receiving this signal, the chip ingeniously converts the infrared light into electrical impulses. These electrical signals effectively serve as a surrogate for the damaged photoreceptor cells, which are the natural light-detecting cells in the eye responsible for transmitting visual information to the brain. In essence, the PRIMA system bypasses the compromised photoreceptors and directly stimulates the remaining functional retinal neurons, thereby restoring a semblance of sight.

The development of the PRIMA project is the culmination of over twenty years of dedicated scientific endeavor, involving countless iterations of prototypes, extensive animal testing, and an initial human trial that paved the way for this more comprehensive study. Dr. Palanker first conceptualized the idea two decades ago, inspired by his work with ophthalmic lasers used to treat various eye disorders. "I realized we should use the fact that the eye is transparent and deliver information by light," he recalled. The profound impact of this long-held vision is evident in his statement: "The device we imagined in 2005 now works in patients remarkably well."

The participants in this latest clinical trial were individuals afflicted with the advanced stage of age-related macular degeneration known as geographic atrophy. This progressive condition relentlessly destroys central vision, impacting over 5 million people globally and standing as the foremost cause of irreversible blindness among older adults. In AMD, the delicate light-sensitive photoreceptor cells in the central retina gradually deteriorate, leaving individuals with only limited peripheral vision. Crucially, however, many of the retinal neurons responsible for processing visual information remain intact. The PRIMA implant strategically leverages these surviving neural pathways.

Measuring a mere 2 by 2 millimeters, the implant is meticulously positioned within the retinal area where photoreceptor loss has occurred. Unlike natural photoreceptors that are sensitive to visible light, the PRIMA chip is designed to detect infrared light emitted by the accompanying smart glasses. "The projection is done by infrared because we want to make sure it’s invisible to the remaining photoreceptors outside the implant," explained Dr. Palanker, underscoring the precise engineering behind the system. This thoughtful design ensures that the prosthetic vision does not interfere with the patient’s remaining natural peripheral vision.

A particularly significant aspect of the PRIMA system is its ability to enable patients to simultaneously utilize both their natural peripheral vision and the newly restored central prosthetic vision. This synergistic combination significantly enhances their spatial awareness, mobility, and overall ability to navigate their environment. "The fact that they see simultaneously prosthetic and peripheral vision is important because they can merge and use vision to its fullest," Dr. Palanker highlighted. Furthermore, the PRIMA implant is photovoltaic, meaning it generates its own electrical current solely from light. This inherent design allows it to operate wirelessly, eliminating the need for external power sources or cumbersome cables that would extend outside the eye, thereby enhancing safety and patient comfort. This self-sustaining, wireless operation represents a significant improvement over earlier generations of artificial eye devices.

The clinical trial itself was rigorous and comprehensive. It included 38 participants, all over the age of 60, who had been diagnosed with geographic atrophy due to age-related macular degeneration and possessed visual acuity worse than 20/320 in at least one eye. Following a period of four to five weeks after the implantation of the chip in one eye, patients began training with the smart glasses. While some individuals were able to discern patterns almost immediately, all participants experienced a gradual improvement in their visual acuity over several months of dedicated training. Dr. Palanker likened this training period to that required for cochlear implants, stating, "It may take several months of training to reach top performance—which is similar to what cochlear implants require to master prosthetic hearing."

The results of the one-year trial were overwhelmingly positive. Of the 32 patients who completed the study, an impressive 27 were able to read. Furthermore, 26 participants demonstrated a clinically meaningful improvement in visual acuity, defined as the ability to read at least two additional lines on a standard eye chart. On average, participants’ visual acuity improved by a remarkable five lines, with one individual experiencing an extraordinary improvement of twelve lines. The participants integrated the prosthesis into their daily lives, using it to read books, decipher food labels, and recognize subway signs. The adjustable features of the smart glasses, including contrast and brightness control, and up to 12 times magnification, proved invaluable. A substantial two-thirds of the participants reported medium to high user satisfaction with the device. While some side effects were noted, including ocular hypertension, tears in the peripheral retina, and subretinal hemorrhage, these were generally not life-threatening and almost all resolved within two months.

Looking towards the future, Dr. Palanker and his team are already working on enhancements to the PRIMA system. Currently, the device provides black-and-white vision, lacking intermediate shades of gray. However, Dr. Palanker is developing software that will soon introduce a full range of grayscale, a crucial step for tasks like face recognition, which he notes is a high priority for patients, second only to reading. He is also engineering chips with higher resolution. The current resolution is limited by pixel size (100 microns) and the number of pixels (378 per chip). Future versions, already tested in rats, aim for pixels as small as 20 microns, boasting up to 10,000 pixels per chip. This advancement is expected to significantly improve visual acuity, potentially enabling patients to achieve 20/80 vision, with electronic zoom bringing them close to 20/20. Dr. Palanker also intends to explore the device’s efficacy for other forms of blindness caused by photoreceptor loss. "This is the first version of the chip, and resolution is relatively low," he acknowledged. "The next generation of the chip, with smaller pixels, will have better resolution and be paired with sleeker-looking glasses."

The groundbreaking study involved a vast network of researchers from esteemed institutions worldwide, including the University of Bonn, Germany; Hôpital Fondation A. de Rothschild, France; Moorfields Eye Hospital and University College London; Ludwigshafen Academic Teaching Hospital; University of Rome Tor Vergata; Medical Center Schleswig-Holstein, University of Lübeck; L’Hôpital Universitaire de la Croix-Rousse and Université Claude Bernard Lyon 1; Azienda Ospedaliera San Giovanni Addolorata; Centre Monticelli Paradis and L’Université d’Aix-Marseille; Intercommunal Hospital of Créteil and Henri Mondor Hospital; Knappschaft Hospital Saar; Nantes University; University Eye Hospital Tübingen; University of Münster Medical Center; Bordeaux University Hospital; Hôpital National des 15-20; Erasmus University Medical Center; University of Ulm; Science Corp.; University of California, San Francisco; University of Washington; University of Pittsburgh School of Medicine; and Sorbonne Université. The research was generously supported by funding from Science Corp., the National Institute for Health and Care Research, Moorfields Eye Hospital National Health Service Foundation Trust, and University College London Institute of Ophthalmology.